InsiderClue
Stocks · Health care · Biological Products, (No Diagnostic Substances)

Maze Therapeutics, Inc.

MAZE Clue Score57
United States Fiscal year ends December CIK 0001842295
$27.11 +4.75% Close, 9 Oct 2026
Alert on the numbers Alert on insider trades
Price $27.11 −5.74% Close, 9 Oct 2026

Closing prices at the end of each trading day, from 31 Jan 2025. Not a live quote. Adjusted for share splits, so the line has no step at a split; dividends are not added back. P/E and P/FCF are the market value over the last full fiscal year's net income or free cash flow, as public on each day, so they step once a year when the annual report comes out. A hatched band marks a stretch with none: a year of net loss, or of cash burnt.

Revenue and profit

What the business sells, and what is left of it. Point at a year for the detail.
RevenueOperating incomeNet income
Fiscal year 2024Revenue167.5Operating income57.6Net income52.2EPS, diluted1.25Fiscal year 2025Operating income−142.9Net income−131.1 −351.0%EPS, diluted−3.05
FY2024FY2025
Revenue 167.5 n/a
Growth
Operating income 57.6 −142.9
Net income 52.2 −131.1
Growth −351.0%
EPS, diluted 1.25 −3.05

Margins

How much of each dollar of revenue it keeps. Point at a year for the detail.
Operating marginNet margin
Fiscal year 2024Operating margin34.4%Net margin31.2%Free cash flow margin44.7%Fiscal year 2025
FY2024FY2025
Operating margin 34.4% n/a
Net margin 31.2% n/a
Free cash flow margin 44.7% n/a

Cash flow

The cash the business makes, what it reinvests, and what it hands back. Point at a year for the detail.
Operating cash flowCapital expenditureFree cash flow
Fiscal year 2024Operating cash flow76.0Capital expenditure−1.1Free cash flow74.8Fiscal year 2025Operating cash flow−111.9Capital expenditure−0.8Free cash flow−112.7 −250.7%
FY2024FY2025
Operating cash flow 76.0 −111.9
Capital expenditure −1.1 −0.8
Free cash flow 74.8 −112.7
Growth −250.7%

Balance sheet

What it holds against what it owes, at each year end. Point at a year for the detail.
Cash
Fiscal year 2024Cash196.8Shareholders’ equity−311.2Fiscal year 2025Cash189.2Shareholders’ equity355.0
FY2024FY2025
Cash 196.8 189.2
Shareholders’ equity −311.2 355.0

In millions of USD, except per-share figures and ratios. Fiscal years, as last filed with the SEC.

Financial statements FY2025 · 10-K

Ratios

Percentages worked out from the filed figures; debt to equity in times. Fiscal years ending December, each column as last filed with the SEC.
Click a line to chart it
Fiscal year FY2024 31 Dec 2024 FY2025 31 Dec 2025
Margins
34.4% n/a
31.9% n/a
31.2% n/a
44.7% n/a
Spending
49.8% n/a
15.8% n/a
0.7% n/a
2.2% n/a
Returns
n/a −36.9%
21.7% −33.0%
Balance and payout
18.1% 10.6%